Q-Line Biotech IPO
Market Sentiment
IPO Details
IPO Reservation
Market Lot Size
Financial Analysis
| Metric | 2023 | 2024 | 2025 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 184.81 | 206.45 | 322.58 | 236.50 |
| Expense | 154.97 | 175.85 | 261.43 | 186.96 |
| Profit (PAT) | 32.10 | 34.44 | 28.13 | 38.69 |
| Total Assets | 251.58 | 339.25 | 455.49 | 561.34 |
| Company | P/E | EPS |
|---|---|---|
| Powerica Limited | 24.45 | 15.26 |
| Cummins India Limited | 64.13 | 72.15 |
| Kirloskar Oil Engines Limited | 43.24 | 33.71 |
| NTPC Green Energy Limited | 129.40 | 0.67 |
| Acme Solar Holdings Limited | 50.74 | 4.55 |
| Adani Green Energy Limited | 101.53 | 8.37 |
Promoters: Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 1,70,74,999 | 96.77% |
Strengths & Risks
- Heavily oversubscribed — 102.5x overall (so far).
- Strong institutional (QIB) demand — 123.9x.
- Revenue grew 56% in the latest reported year.
- Solid profit margin — 8.7%.
- Strong return on equity — 18%.
No major red flags in the available data.
Auto-generated from live GMP, subscription, valuation and financial data. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry. The firm is known for manufacturing and supplying In-Vitro Diagnostic (IVD) products, medical diagnostic equipment, reagents, rapid test kits, and pathology instruments. The firm has been known to offer high-quality products and services at an affordable price range. Q-Line Biotech has over 15 years of experience in the diagnostic industry and has served 150+ national and international clients. Moreover, the company also has 12 years of experience in developing and manufacturing various products. Its product range includes haematology, POC testing, clinical chemistry, molecular diagnostics, rapid tests, ELISA, and special diagnostics.
| Purpose | Amount (Cr) |
|---|---|
| To meet Working Capital requirements | 110.00 |
| Repayment of certain borrowing availed by the Company, in part or full | 90.00 |
| General Corporate Purpose | - |
Resources & Documents
Q-Line Biotech Ltd., 298-281,, Transport Nagar,, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, 226012
Q-Line Biotech has set a price band of Rs 326–Rs 343 per share for an issue size of Rs 214 crore. The stock listed with a 31.78% gain versus its issue price on May 29, 2026.
Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry. The firm is known for manufacturing and supplying In-Vitro Diagnostic (IVD) products, medical diagnostic equipment, reagents, rapid test kits, and pathology instruments.
The issue is promoted by Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal with Hem Securities Ltd., Share India Capital Services Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards To meet Working Capital requirements (Rs 110 crore) and Repayment of certain borrowing availed by the Company, in part or full (Rs 90 crore).
Grey market is quoting a premium of +Rs 125 (+36.4% over issue price), up Rs 15 from the previous session. Final subscription data records overall subscription at 102.48x, retail at 71.42x, QIB at 123.94x, NII at 146.33x.
On fundamentals, the company is posting revenue growth of 56.3%, a profit margin of 8.7%, return on equity of 17.7% in its most recent reported period. Listed peers in this segment include Powerica Limited (P/E 24.45x) and Cummins India Limited (P/E 64.13x) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
Our data-driven engine currently flags this issue as a Subscribe call — the composite picture tilts favourable, though not without some caveats. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Understanding Grey Market Premium (GMP)
The Grey Market Premium (GMP) is an unofficial indicator of how an IPO's shares are trading in the grey market before they are officially listed on a stock exchange. It reflects investor sentiment and demand for the IPO shares ahead of listing day.
How does it work? The grey market is an informal, over-the-counter market where investors buy and sell IPO shares before the official listing date. If an IPO has a positive GMP, it suggests that investors expect the stock to list above its issue price. A negative GMP indicates expectations of a listing below the issue price.
Example: If an IPO has an issue price of ₹100 and the GMP is ₹50, the expected listing price would be approximately ₹150 (issue price + GMP). This translates to an estimated listing gain of 50%.
Factors that influence GMP:
- Subscription levels — Higher subscription typically drives GMP up
- Market conditions — Bullish markets tend to boost GMP across all IPOs
- Company fundamentals — Strong financials and growth potential attract premium
- Industry sentiment — Positive outlook for the sector can increase demand
- IPO pricing — Reasonably priced IPOs relative to peers tend to command higher GMP
Disclaimer: GMP is an unofficial metric from the grey market and is not regulated by SEBI or any stock exchange. GMP values fluctuate frequently and should not be the sole basis for investment decisions. Always consider company fundamentals, financial health, and your own risk appetite before investing in any IPO.
Related IPO
No comments yet. Be the first to share your opinion!